Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Regulatory News (SYNC)

Share Price Information for Syncona (SYNC)

Share Price is delayed by 15 minutes
Get Live Data
98.20    2.20 (2.29%)
Bid:
97.60
Ask:
98.50
Spread: 0.90 (0.922%)
Market Cap: £597.25m
SYNC Live PriceLast checked at - London Stock Exchange

Intraday Syncona Share Chart

Directorate Change

31 Dec 2021 07:00

RNS Number : 6395W
Syncona Limited
31 December 2021
 

Syncona Limited

 

Directorate Change

 

31 December 2021

 

Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life science, notes that as previously announced, Nigel Keen and Nicholas Moss step down as Non-Executive Directors on 31 December 2021.

 

Virginia Holmes will become Senior Independent Director and Gian Piero Reverberi will become Chair of the Remuneration Committee, in each case from 1 January 2022.

 

[ENDS]

 

Enquiries

 

Syncona Ltd

Natalie Garland-Collins / Fergus Witt

Tel: +44 (0) 7714 916615

 

FTI Consulting

Ben Atwell / Tim Stamper

Tel: +44 (0) 20 3727 1000

 

Company Secretary

Citco Fund Services (Guernsey) Limited

Company Secretary

Tel: +44 (0) 1481 758228

 

About Syncona:

Syncona's purpose is to invest to extend and enhance human life. We do this by founding and building companies to deliver transformational treatments to patients in areas of high unmet need.

 

Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFELFSDEFSEEE
Date   Source Headline
19th Mar 20247:00 amRNSTransaction in Own Shares
18th Mar 20247:00 amRNSTransaction in Own Shares
15th Mar 20247:00 amRNSTransaction in Own Shares
14th Mar 202411:05 amRNSAutolus reports full year 2023 Financial Results
14th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20247:00 amRNSTransaction in Own Shares
12th Mar 20247:00 amRNSTransaction in Own Shares
11th Mar 20247:00 amRNSTransaction in Own Shares
8th Mar 20247:00 amRNSTransaction in Own Shares
7th Mar 20247:00 amRNSTransaction in Own Shares
6th Mar 20245:22 pmRNSDirector Declaration
6th Mar 20247:00 amRNSTransaction in Own Shares
4th Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 20241:30 pmRNSTotal Voting Rights
22nd Feb 20247:00 amRNSTransaction in Own Shares
21st Feb 20247:00 amRNSTransaction in Own Shares
20th Feb 202412:02 pmRNSAcquisition of Freeline Becomes Effective
20th Feb 20247:00 amRNSTransaction in Own Shares
19th Feb 20247:00 amRNSTransaction in Own Shares
16th Feb 20247:00 amRNSTransaction in Own Shares
15th Feb 20247:00 amRNSTransaction in Own Shares
14th Feb 20247:00 amRNSTransaction in Own Shares
13th Feb 20247:00 amRNSTransaction in Own Shares
9th Feb 20247:00 amRNSTransaction in Own Shares
8th Feb 202412:53 pmRNSAutolus offering (Amendment)
8th Feb 202412:13 pmRNSAutolus announces pricing of public offering
8th Feb 202412:05 pmRNSBeacon presents 12-month clinical data
8th Feb 202410:50 amRNSAutolus announces Strategic Collaboration
8th Feb 20247:00 amRNSThird Quarter Update
8th Feb 20247:00 amRNSTransaction in Own Shares
7th Feb 20247:00 amRNSTransaction in Own Shares
6th Feb 20247:00 amRNSTransaction in Own Shares
5th Feb 20247:00 amRNSTransaction in Own Shares
2nd Feb 20247:00 amRNSTransaction in Own Shares
1st Feb 20242:02 pmRNSTotal Voting Rights
1st Feb 20247:00 amRNSTransaction in Own Shares
31st Jan 20247:00 amRNSTransaction in Own Shares
30th Jan 20247:00 amRNSTransaction in Own Shares
29th Jan 20247:00 amRNSTransaction in Own Shares
26th Jan 20247:00 amRNSTransaction in Own Shares
25th Jan 20247:00 amRNSTransaction in Own Shares
24th Jan 20247:00 amRNSTransaction in Own Shares
23rd Jan 20247:00 amRNSTransaction in Own Shares
22nd Jan 202412:05 pmRNSAutolus announces acceptance of BLA for obe-cel
22nd Jan 20247:00 amRNSTransaction in Own Shares
19th Jan 20247:00 amRNSFreeline announces further data
18th Jan 20247:00 amRNSTransaction in Own Shares
17th Jan 20247:00 amRNSTransaction in Own Shares
16th Jan 20247:00 amRNSTransaction in Own Shares
15th Jan 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.